NorthWest Biotherapeutics Inc (NWBO)

[RRRichmond]

Key points of Dr. Prins interview.

-- A tremendous, respectful, and mutually supportive working arrangement with NWBO. Linda knows how to work with researchers. (My words).

-- UCLA has done little work to date with Direct. Looking forward to it and preparing a Protocol for a new NWBO sponsored trial (possibly with the cosponsorship of the adjuvant maker) with adjuvants.

-- Made it clear that NWBO owns the commercialization of DCVax.

-- Results for Phase 1/2 DCVax-L trial are due shortly. No hint of him knowing the results. He is a pro researcher. Everything is in the data.

-- The 5000 stored tumors and most stored tumors are frozen for research purposes. These are not lysate capable. Patient must ordinarily request the saving of tissue.

--BMY researchers were aware and complementary toward NWBO's trial standards. Called it, "certainty one of the best." Referring to its structural integrity.

-- Several attendees had doubts about the Novo "helmet" trial getting stopped for 3 months of efficacy. They all questioned the data.

--Immunotherapy was at the forefront of discussion at SNOW. NWBIO has the research communities attention. Everyone waiting for results, end of 2015. Researchers here are only interested in complete data. When I mentioned 149 events and the first interim review. Several researchers, including Prins, just looked at me. They don't think that way. He did not realize that a review was being done at 149 events and did not see the importance that we place on the event. (Only the companies do.)